Jeremy C. Parker

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund et al. · The Lancet Diabetes & Endocrinology · 2019 · 342 citations · Full text

Medicine, Nephrology, Pharmacology +13

Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort

Zhuo Chen, Andrew D. Paterson, John M. Lachin et al. · Proceedings of the National Academy of Sciences · 2016 · 240 citations · Full text

Life Sciences, Genetics, Molecular Biology +15

In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo

Rémi Villenave, Surendran Thavagnanam, Séverine Sarlang et al. · Proceedings of the National Academy of Sciences · 2012 · 209 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17

Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide.

Walter C. Soeller, Juliette Janson, S E Hart et al. · Diabetes · 1998 · 142 citations

Medicine, Endocrinology, Molecular Biology +16

Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study

Jonathan Q. Purnell, Barbara H. Braffett, Bernard Zinman et al. · Diabetes Care · 2017 · 118 citations · Full text

Medicine, Chronic Disease Control, Chronic Disease Prevention +17